Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Shionogi Nabs Rights to Osaka Upstart’s Tissue Regeneration-Inducing Peptide
March 16, 2018
-
BUSINESS Japan Likely the Only Negative Growth Pharma Market in 2018-2022: IQVIA
March 16, 2018
-
BUSINESS Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
March 15, 2018
-
BUSINESS Gilead Japan Rolling Up Its Sleeves for Foray into Oncology/Inflammation Market
March 14, 2018
-
TRENDS Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
March 13, 2018
-
BUSINESS Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
March 9, 2018
-
BUSINESS Foreign Drug Makers Increased Market Share to Over 60% among Top 20 Makers in 2017
March 9, 2018
-
BUSINESS Torii’s Futhan to Get 43.4% Price Cut in April, Urinorm 24.6%: Top 5 Product Survey
March 8, 2018
-
BUSINESS Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey
March 7, 2018
-
REGULATORY Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
-
REGULATORY 314 APIs Eligible for Price Maintenance Premium in FY2018, Down from 416
March 5, 2018
-
REGULATORY Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash
March 5, 2018
-
BUSINESS Japan Ethical Drug Sales Slip 1.0% in 2017, Harvoni Drops Out of Top 10 List: IQVIA
March 2, 2018
-
BUSINESS Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs
March 2, 2018
-
ACADEMIA Nephrology Society Compiles New Drug Development Guidelines for Advanced CKD; Will Guidelines for Early-Stage CKD Follow?
March 1, 2018
-
BUSINESS Kissei Makes Full Foray into IBD Arena with Rectabul, Set to Enrich “Unmet Needs” Portfolio
February 27, 2018
-
BUSINESS Nomura Picked as Next Chief of Sumitomo Dainippon, Vows to Build Peripheral Healthcare Biz
February 26, 2018
-
REGULATORY Shionogi’s Single-Dose Flu Med Gets Accelerated OK
February 26, 2018
-
TRENDS Countering Abilify Cliff, Otsuka Sees New Drug Franchise Set Stage for Growth Path
February 23, 2018
-
ACADEMIA Major Drug Makers to Join in AMED Project to Develop “Organs on Chips” as New Tools for Drug Discovery
February 22, 2018
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…